Get the Stockscreener App
1.1921
15.74%
0.1621
After Hours:
1.21
0.0179
+1.50%
Citius Oncology Inc stock is traded at $1.1921, with a volume of 164.68K.
It is up +15.74% in the last 24 hours and up +0.18% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.03
Open:
$1.02
24h Volume:
164.68K
Relative Volume:
1.03
Market Cap:
$79.14M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.84%
1M Performance:
+0.18%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.02
$1.20
1-Week Range:
$1.01
$1.27
52-Week Range:
$0.925
$2.87
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(347) 627-0058
Address
420 LEXINGTON AVE,, NEW YORK
Citius Oncology Inc Stock (CTOR) Latest News
CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India
CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Nasdaq
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News
Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
Citius Oncology Inc. (CTOR) requires closer examination - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.00, Reflecting a -11.11 Downturn - The Dwinnex
Citius Oncology Inc. completes strategic acquisition By Investing.com - Investing.com Australia
Citius Oncology Inc. completes strategic acquisition - Investing.com
Citius Pharma finalizes $675M oncology unit spinoff - NJBIZ
Closing Bell Recap: Citius Oncology Inc. (CTOR) Ends at 2.47, Reflecting a -22.81 Downturn - The Dwinnex
Citius merges oncology subsidiary with TenX Keane - Yahoo Finance
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology - citybiz
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. - Yahoo Finance
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Quantisnow
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - StockTitan
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update - ForexTV.com
TenX Keane addresses trading halt, continues toward combination closing - TipRanks
New Ontak on track as Citius wins FDA’s nod for Lymphir in CTCL - BioWorld Online
US FDA approves Citius' therapy for rare blood cancer - Reuters.com
Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - PR Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
Citius Pharmaceuticals Advances Oncology Spinoff Through Merger with TenX Keane - Vancity Buzz
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology - Nasdaq
Citius Pharma secures majority in TenX merger deal - Investing.com India
Citius Pharma secures majority in TenX merger deal By Investing.com - Investing.com Australia
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.88%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):